ABBVIE (4AB BE) stock market data APIs
€187.7723
-2.09(-1.1%)
as of September 18, 2025
Try our APIs with
free plan!
ABBVIE Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for 4AB.BE.
Prev. Close
187.7723
Open
185.686
High
187.7723
Low
185.4598
52 wk Range
145.6166-200.2474
Market Cap
196 410 M
Dividends (Yield)
0.0457
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ABBVIE data using free add-ons & libraries
Get ABBVIE Fundamental Data
ABBVIE Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ABBVIE News
New
J&J Expects Innovative Medicines Growth Despite Stelara LOE: Here's Why
Johnson & Johnson’s JNJ multibillion-dollar immunology drug, Stelara, lost patent exclusivity in the United States this year. It is approved for treating moderate-to-severe plaque psoriasis, active ...
BMO Lifts AbbVie Inc. (ABBV) Price Target to $240 After Rinvoq Litigation Win
AbbVie Inc. (NYSE:ABBV) is among the high growth mega cap stocks you can buy and hold for the next 3 years. Evan Seigerman, an analyst at BMO Capital, increased the price target on AbbVie Inc. (NYSE:A...
AbbVie (ABBV) Ascends While Market Falls: Some Facts to Note
AbbVie (ABBV) closed at $220.81 in the latest trading session, marking a +2.1% move from the prior day. This move outpaced the S&P 500's daily loss of 0.1%. At the same time, the Dow added 0.57%, and ...
Oruka Therapeutics, Up 9%, Is Trying To Take On AbbVie's Biggest Moneymaker
Biotech stock Oruka Therapeutics skyrocketed Wednesday on promising test results for what could be a once-annual shot to treat psoriasis. Continue Reading View Comments
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
